191 related articles for article (PubMed ID: 21600929)
1. Production and characterization of virus-like particles and the P domain protein of GII.4 norovirus.
Koho T; Huhti L; Blazevic V; Nurminen K; Butcher SJ; Laurinmäki P; Kalkkinen N; Rönnholm G; Vesikari T; Hytönen VP; Kulomaa MS
J Virol Methods; 2012 Jan; 179(1):1-7. PubMed ID: 21600929
[TBL] [Abstract][Full Text] [Related]
2. Self-assembly of the recombinant capsid protein of a swine norovirus into virus-like particles and evaluation of monoclonal antibodies cross-reactive with a human strain from genogroup II.
Almanza H; Cubillos C; Angulo I; Mateos F; Castón JR; van der Poel WH; Vinje J; Bárcena J; Mena I
J Clin Microbiol; 2008 Dec; 46(12):3971-9. PubMed ID: 18842943
[TBL] [Abstract][Full Text] [Related]
3. Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains.
LoBue AD; Lindesmith L; Yount B; Harrington PR; Thompson JM; Johnston RE; Moe CL; Baric RS
Vaccine; 2006 Jun; 24(24):5220-34. PubMed ID: 16650512
[TBL] [Abstract][Full Text] [Related]
4. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
[TBL] [Abstract][Full Text] [Related]
5. Purification of norovirus-like particles (VLPs) by ion exchange chromatography.
Koho T; Mäntylä T; Laurinmäki P; Huhti L; Butcher SJ; Vesikari T; Kulomaa MS; Hytönen VP
J Virol Methods; 2012 Apr; 181(1):6-11. PubMed ID: 22265819
[TBL] [Abstract][Full Text] [Related]
6. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis.
Blazevic V; Lappalainen S; Nurminen K; Huhti L; Vesikari T
Vaccine; 2011 Oct; 29(45):8126-33. PubMed ID: 21854823
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of norovirus GII-4 antibodies in Finnish children.
Nurminen K; Blazevic V; Huhti L; Räsänen S; Koho T; Hytönen VP; Vesikari T
J Med Virol; 2011 Mar; 83(3):525-31. PubMed ID: 21264875
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and protective potency of Norovirus GII.17 virus-like particle-based vaccine.
Chen W; Kang T; Yuan R; Shao C; Jing S
Biotechnol Lett; 2020 Jul; 42(7):1211-1218. PubMed ID: 32088791
[TBL] [Abstract][Full Text] [Related]
9. Norovirus GII.4 antibodies in breast milk and serum samples: their role preventing virus-like particles binding to their receptors.
Khodayar-Pardo P; Martínez-Costa C; Carmona-Vicente N; Buesa J
Pediatr Infect Dis J; 2014 Jun; 33(6):554-9. PubMed ID: 24830517
[TBL] [Abstract][Full Text] [Related]
10. Self-assembly of the recombinant capsid protein of a bovine norovirus (BoNV) into virus-like particles and evaluation of cross-reactivity of BoNV with human noroviruses.
Han MG; Wang Q; Smiley JR; Chang KO; Saif LJ
J Clin Microbiol; 2005 Feb; 43(2):778-85. PubMed ID: 15695679
[TBL] [Abstract][Full Text] [Related]
11. Functionality and avidity of norovirus-specific antibodies and T cells induced by GII.4 virus-like particles alone or co-administered with different genotypes.
Malm M; Tamminen K; Heinimäki S; Vesikari T; Blazevic V
Vaccine; 2018 Jan; 36(4):484-490. PubMed ID: 29246474
[TBL] [Abstract][Full Text] [Related]
12. Expression and antigenicity of virus-like particles of norovirus and their application for detection of noroviruses in stool samples.
Kamata K; Shinozaki K; Okada M; Seto Y; Kobayashi S; Sakae K; Oseto M; Natori K; Shirato-Horikoshi H; Katayama K; Tanaka T; Takeda N; Taniguchi K
J Med Virol; 2005 May; 76(1):129-36. PubMed ID: 15778983
[TBL] [Abstract][Full Text] [Related]
13. Identification and characterization of a native epitope common to norovirus strains GII/4, GII/7 and GII/8.
Li X; Zhou R; Wang Y; Sheng H; Tian X; Li H; Qiu H
Virus Res; 2009 Mar; 140(1-2):188-93. PubMed ID: 19121346
[TBL] [Abstract][Full Text] [Related]
14. Biological and immunological characterization of norovirus major capsid proteins from three different genotypes.
Huo Y; Wan X; Ling T; Shen S
Microb Pathog; 2016 Jan; 90():78-83. PubMed ID: 26616166
[TBL] [Abstract][Full Text] [Related]
15. Investigation of norovirus replication in a human cell line.
Katayama K; Hansman GS; Oka T; Ogawa S; Takeda N
Arch Virol; 2006 Jul; 151(7):1291-308. PubMed ID: 16502284
[TBL] [Abstract][Full Text] [Related]
16. Expression and purification of norovirus virus like particles in Escherichia coli and their immunogenicity in mice.
Huo Y; Wan X; Ling T; Wu J; Wang W; Shen S
Mol Immunol; 2018 Jan; 93():278-284. PubMed ID: 28802994
[TBL] [Abstract][Full Text] [Related]
17. Norovirus GII.4 strain antigenic variation.
Lindesmith LC; Donaldson EF; Baric RS
J Virol; 2011 Jan; 85(1):231-42. PubMed ID: 20980508
[TBL] [Abstract][Full Text] [Related]
18. Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice.
Guo L; Wang J; Zhou H; Si H; Wang M; Song J; Han B; Shu Y; Ren L; Qu J; Hung T
Vaccine; 2008 Jan; 26(4):460-8. PubMed ID: 18160189
[TBL] [Abstract][Full Text] [Related]
19. Serological Correlates of Protection against a GII.4 Norovirus.
Atmar RL; Bernstein DI; Lyon GM; Treanor JJ; Al-Ibrahim MS; Graham DY; Vinjé J; Jiang X; Gregoricus N; Frenck RW; Moe CL; Chen WH; Ferreira J; Barrett J; Opekun AR; Estes MK; Borkowski A; Baehner F; Goodwin R; Edmonds A; Mendelman PM
Clin Vaccine Immunol; 2015 Aug; 22(8):923-9. PubMed ID: 26041041
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a Norovirus-specific monoclonal antibody that exhibits wide spectrum binding activities.
Zheng L; Wang W; Liu J; Chen X; Li S; Wang Q; Huo Y; Qin C; Shen S; Wang M
J Med Virol; 2018 Apr; 90(4):671-676. PubMed ID: 29236287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
